GeneTether Therapeutics Inc. announced a non-brokered private placement at a price of CAD 0.60 per share on March 22, 2022. The transaction will include participation from certain directors and officers of the company. Each unit consists of one common share and one common share purchase warrant.

Each warrant will entitle the holder to acquire one additional common share of the company at a purchase price of CAD 0.72 per share for a period of 36 months following the closing date. The securities are subject to a statutory hold period of four months and a day, in accordance with applicable securities laws. The transaction is subject to approval of Canadian Stock Exchange.